You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Controlling mechanical signal transduction to treat osteoarthritis

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Early Warning system for detecting pre-eclampsia

    SBC: CONVERGENT ENGINEERING, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. EOIR Debris Management during ascent phase for C2BMC

    SBC: APPLIED MATHEMATICS, INC.            Topic: MDA12T004

    We propose to develop algorithms to improve debris management for electro-optical/infrared sensors (EO/IR) within C2BMC. Our goal is to improve fire control solutions, increase the quality of communicated sensor information, and reduce communication demands. We characterize the pre-intercept debris field mathematically by expressing the debris fields viewed on the sensor"s focal plane as 2D elli ...

    STTR Phase I 2013 Department of DefenseMissile Defense Agency
  4. Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk

    SBC: ZENAGENE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Evaluation of a new class of molecules for treating MRSA infective endocarditis

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Identification of potent and selective GLI1 inhibitors

    SBC: Zen-Bio, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in a vast array of cancer types, including small-cell lung, pancreatic, oesophageal, prostate, breast, colon, liver and ovarian cancers. Hh signaling is now implicated in approximately 20-25% of all can ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Innovative Polishing Technology for Fabrication of High Performance Epi-ready GaSb Substrates

    SBC: Sinmat Inc            Topic: MDA12T003

    Antimony containing III-V semiconducting compounds are particularly attractive for the fabrication of a wide variety of electronic and optoelectronic devices such as photo detectors operating in the long wave infrared wavelength (12-32µm) range. The production of epi quality GaSb wafers still remains one of the important problems for rapid commercialization of GaSb devices. Sinmat Inc. proposes a ...

    STTR Phase I 2013 Department of DefenseMissile Defense Agency
  8. Medical Images, HTML5, and Clinical Trial Remote Collaboration

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Medical drugs and devices are regulated by the U.S. Food and Drug Administration (FDA) based on data from multicenter clinical trials. In 2010, U.S. spending on clinical trials was approximately 25 billion. Over the past decade the efficiency of clinical trials has been improved by electronic data capture (EDC) systems, whose use has increased from 38% to 61% ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Nogo Decoy Receptor Therapy for the Treatment of Glaucoma

    SBC: RENETX BIO, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): The objective of this phase I STTR application is to continue assessment of the relevance and feasibility of Nogo decoy receptor therapy for the treatment of glaucoma. The secondary objective is to obtain pharmacokinetic data important for designing additional preclinical efficacy studies and formulating a drug development plan for glaucoma. Our long term objec ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government